scholarly journals Coronary Artery Calcium - From Screening to a Personalized Shared Decision-Making Tool: The New American Prevention Guidelines

2018 ◽  
Author(s):  
Marcio Sommer Bittencourt ◽  
Michael J. Blaha ◽  
Khurram Nasir
Keyword(s):  
Decision Making ◽  
Coronary Artery ◽  
Shared Decision Making ◽  
Coronary Artery Calcium ◽  
Shared Decision ◽  
Prevention Guidelines ◽  
Decision Making Tool

scholarly journals Coronary Artery Calcium and Shared Decision Making

2016 ◽  
Vol 9 (5) ◽  
pp. 637-639 ◽  
Author(s):  
Harvey S. Hecht ◽  
Leslee J. Shaw ◽  
Y. Chandrashekhar ◽  
Jagat Narula
Keyword(s):  
Decision Making ◽  
Coronary Artery ◽  
Shared Decision Making ◽  
Coronary Artery Calcium ◽  
Shared Decision

scholarly journals The Evolving View of Coronary Artery Calcium: A Personalized Shared Decision-Making Tool in Primary Prevention

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
Omar Dzaye ◽  
Cara Reiter-Brennan ◽  
Albert D. Osei ◽  
Olusola A. Orimoloye ◽  
S. M. Iftekhar Uddin ◽  
...  
Keyword(s):  
Decision Making ◽  
Coronary Artery ◽  
Primary Prevention ◽  
Shared Decision Making ◽  
Coronary Artery Calcium ◽  
Risk Groups ◽  
Intermediate Risk ◽  
Shared Decision ◽  
Management Guideline ◽  
Cholesterol Management

The 2018 American Heart Association and American College of Cardiology (AHA/ACC) cholesterol management guideline considers current evidence on coronary artery calcium (CAC) testing while incorporating learnings from previous guidelines. More than any previous guideline update, this set encourages CAC testing to facilitate shared decision making and to individualize treatment plans. An important novelty is further separation of risk groups. Specifically, the current prevention guideline recommends CAC testing for primary atherosclerotic cardiovascular disease (ASCVD) prevention among asymptomatic patients in borderline and intermediate risk groups (5–7.5% and 7.5–20% 10-year ASCVD risk). This additional sub-classification reflects the uncertainty of treatment strategies for patients broadly considered to be “intermediate risk,” as treatment recommendations for high and low risk groups are well established. The 2018 guidelines, for the first time, clearly recognize the significance of a CAC score of zero, where intensive statin therapy is likely not beneficial and not routinely recommended in selected patients. Lifestyle modification should be the focus in patients with CAC = 0. In this article, we review the recent AHA/ACC cholesterol management guideline and contextualize the transition of CAC testing to a guideline-endorsed decision aid for borderline-to-intermediate risk patients who seek more definitive risk assessment as part of a clinician-patient discussion. CAC testing can reduce low-value treatment and focus primary prevention therapy on those most likely to benefit.

Selective Use of Coronary Artery Calcium Testing for Shared Decision Making: Guideline Endorsed and Ready for Prime Time

2019 ◽  
Vol 170 (4) ◽  
pp. 262 ◽  
Author(s):  
Rhanderson Cardoso ◽  
Khurram Nasir ◽  
Roger S. Blumenthal ◽  
Michael J. Blaha
Keyword(s):  
Decision Making ◽  
Coronary Artery ◽  
Shared Decision Making ◽  
Coronary Artery Calcium ◽  
Prime Time ◽  
Shared Decision

Development of a shared decision‐making tool in vitiligo: an international study

2021 ◽  
Author(s):  
J. Shourick ◽  
M. Ahmed ◽  
J. Seneschal ◽  
T. Passeron ◽  
N. Andreux ◽  
...  
Keyword(s):  
Decision Making ◽  
Shared Decision Making ◽  
International Study ◽  
Shared Decision ◽  
Decision Making Tool

Development and acceptability of a shared decision-making tool for commercial peanut allergy therapies

2020 ◽  
Vol 125 (1) ◽  
pp. 90-96 ◽  
Author(s):  
Matthew Greenhawt ◽  
Marcus Shaker ◽  
Tonya Winders ◽  
Don A. Bukstein ◽  
Ray S. Davis ◽  
...  
Keyword(s):  
Decision Making ◽  
Shared Decision Making ◽  
Peanut Allergy ◽  
Shared Decision ◽  
Decision Making Tool
Sign in / Sign up

Export Citation Format

Share Document